Introduction {#S0001}
============

Despite many efforts undertaken to control Human Immune-deficiency Virus (HIV) epidemic, it remains to be the major global public health challenge.[@CIT0001],[@CIT0002] Highly Active Anti-Retroviral Therapy (HAART) is those medications given to increase the life expectancy of children infected with HIV. Globally, scaling up Anti-Retroviral Therapy (ART) services has been increased markedly, particularly in sub-Saharan Africa.[@CIT0002]--[@CIT0004]

Treatment failure refers to sub-optimal response or a lack of sustained response to therapy excluding cases of Immune Reconstitution Inflammatory Syndrome (IRIS). It can be determined through the examination of clinical failure (clinical criteria), immunologic failure (CD4 criteria), virologic failure (viral load criteria), or a combination of all.[@CIT0005],[@CIT0006]

With expanding access to pediatric ART, children are more likely to develop treatment failure, subsequently requiring 2nd line therapy.[@CIT0005],[@CIT0007]--[@CIT0011] Of the 1.5 million children estimated to require ART by 2020, around 20% are expected to experience VF at some point.[@CIT0012]

Recommending potent and effective second-line regimens for infants and children is difficult because treatment options are largely non-existent in most low-income countries.[@CIT0013]--[@CIT0015] Consequently, this challenge emphasizes the significance of choosing potent first-line regimens and the necessity to make maximal efforts to ensure increased durability of first-line regimens.[@CIT0014]

Ethiopia is one of the high HIV-burden countries and does not have appropriate ART drug formulations for children beyond the 2nd line.[@CIT0007] The diagnosis of ART failure is infrequent in most centers of Ethiopia.[@CIT0016]--[@CIT0019] In addition to this, all available studies estimated treatment failure only by clinical and CD4 criteria.[@CIT0018],[@CIT0020] For this reason, the ART failure rate is expected to be underestimated in our country. Thus, unless we perform best to increase the durability and effectiveness of first-line regimens, we may end up with null or limited options to increase the survival of HIV--infected children and to control the epidemic plus short of hitting the UNAIDS 2020 targets.[@CIT0021]--[@CIT0023] Furthermore, I could not find a single study conducted in the Tigray region with this topic. This implies that we need to research to determine the incidence of treatment failure and to identify factors that provoke treatment failure. Thereupon, this study intended to fill the aforementioned gap.

Methods {#S0002}
=======

An institution-based retrospective follow-up study was employed at general hospitals of Mekelle and Southern zones of Tigray region, Ethiopia from December 2018--June 2019 by reviewing five years \[2014--2018\] follow up data of children below 18 years of age. The total population of Mekelle city was 423,172; of which 214,141 were males and 208,931 were females. Whereas, 756,515 people live in the Southern zone of the Tigray region; of those 371,692 were males and 384,823 were females.[@CIT0024] There are five general governmental hospitals in the two zones, all of which provide ART care services.

Study Population {#S0002-S2001}
----------------

All HIV/AIDS infected children below 18 years who were taking first-line ART at selected public general hospitals of Mekelle and Southern zones of Tigray region and who had a minimum of two follow-up visits with at least one visit six months post-initiation of ART. Those charts of children who have not at least one of the three key failure indicator variables (WHO clinical stage, CD4 count and VL) were excluded.

Sample Size Determination and Sampling Procedure {#S0002-S2002}
------------------------------------------------

The sample size was calculated based on a Log rank test considering assumptions of the Cox proportional hazard model by using STATA version 13 software considering 95% CI and 80% power. Opportunistic infection at baseline which yields the largest sample size was considered as a significant predictor of failure, with an HR of 2.3 and proportion of failure among no OI group 6.4% (ie probability of failure among children without OI =0.064) and failure among OI group 11% from a study finding in Amhara region.[@CIT0025] Considering a 5% non-response rate, in favor of incomplete information, the total sample size required for the study was 400 with an expected number of events, E=47.

A cluster sampling technique was employed considering each hospital as a cluster. Among those clusters, three hospitals were selected by using the lottery method and all charts of children taking ART in the previous five years at all of the selected hospitals (clusters) were incorporated in the study for review.

Operational Definitions and Measurements {#S0002-S2003}
----------------------------------------

**Events were** HIV/AIDS infected children below 18 years who experienced treatment failure based on WHO criteria either clinical (new or repeated event indicative of WHO stage 3 or 4), immunologic (CD4 \<200cells/L for older children and \<100 cells/L for under 5), and/or virologic criteria (VL\>1000copies/mL) after 6 months of effective ART treatment such that at least one criterion should be fulfilled.[@CIT0005]

**Censored** were those who did not experienced treatment failure during follow-up including defaulters, transfer outs, died, exceed 18 years of age during follow up, on first-line at the end of follow-up and switchers due to factors other than first-line ART failure (eg primary non-response to ART, anti-TB treatment while on ART, drug resistance e.t.c.). The time to occurrence of an event or censored cases was measured in months.

**Switch** was considered when (i) commencement of ≥2 new drugs including a class-switch from PI to NNRTI or vice versa even without failure, (ii) class-switch from NNRTI to PI or vice versa only, with reason documented as treatment failure or (iii) change of both NRTIs and change from RTV to LPV/r with reason documented as treatment failure. A patient was considered a defaulter if no follow-up visit for ≥ 3 months and adherence was measured based on the 2017 national ART score cut-offs.[@CIT0005],[@CIT0007]

Data Collection Instruments and Procedure {#S0002-S2004}
-----------------------------------------

A data extraction checklist was developed from the national comprehensive HIV treatment guideline,[@CIT0007] ART registration booklet, ART monitoring multi-chart and reviewing related articles. The extraction tool was comprised of socio-demographic characteristics, clinical characteristics, treatment-related and other factors. The lists of participants were taken from the ART data clerk and MRN or unique ART numbers were used to find charts from the hospital card room. Four data collectors (BSc nurses) and one supervisor (ART trained BSc) were recruited and the data collection was accomplished from April 1--26/2019.

Data Processing, Analysis, Interpretation, and Presentation {#S0002-S2005}
-----------------------------------------------------------

At the end of data collection, data were entered into Epi-data manager version 4.4 and exported to and cleaned, edited, coded, and analyzed using STATA version 14. Exploratory data analysis was carried out to check the levels of missing values, the presence of influential outliers, and normality. Then the data were described using relative frequency, percent and median with interquartile range. Life-table was constructed to estimate probabilities of failure at different time intervals. Kaplan Meier's failure curve was used to estimate median failure time during the treatment period and Log rank tests to compare survival curves for the presence of difference in the incidence of failure among the groups.

The bi--variable analysis was done to identify associations between dependent and each independent variable. Variables, significant at P ≤0.05 level in the bi--variable analysis, were included in multivariable analysis, to identify independent predictors of failure. This was to maintain the balance between the amount of available information (96 events) and the number of parameters (variables) to be estimated. Moreover, it helps to decrease the junk effect as there were significant numbers of candidate variables with this cut-off point which were eligible to be recruited in the final model and therefore no need to consider a p-value of below 0.25 in this case.

Multi co-linearity was checked using the VIF command (mean vif=1.73). The Cox regression model for its fitness to the data was checked using the Cox-Snell residuals. Furthermore, proportional hazard assumptions were checked using the global test with a value of p\> χ^2^ =0.3208. The Log-likelihood test was significant at prob \> chi2 = 0.0000. Generally, we could conclude that the final model fits the data successfully. In the multi--variable analysis, any statistical test was considered significant at P ≤0.05. Then, the association was summarized by using adjusted hazard ratio and statistical significances tested at 95% CI. Finally, the findings were presented using tables, graphs, and texts.

Data Quality Assurance {#S0002-S2006}
----------------------

To assure the quality of data, data collectors and supervisors were trained about how and what information they should collect from the medical records for one day. The checklist was pretested on 5% (21) of randomly selected charts, which were not included in the actual study. Completeness of each collected data was audited at the end of each day by the principal investigator and supervisor. Whenever there appear incompleteness and uncertainty of recording, the filled information formats were cross-checked with source data soon. Individual records with incomplete data during data collection were excluded.

Ethical Consideration {#S0002-S2007}
---------------------

The study was carried out after getting ethical approval (ERC 1272/2019) from the institutional review board (IRB) of Mekelle University, college of health sciences. After approval by IRB, an official letter of co-operation was written to each selected hospital from the school of nursing and permission was received. Then, data were collected after getting permission from selected hospitals on behalf of patients and respective units of each hospital since the study was conducted through a review of medical records. Data coding and aggregate reporting were used so that names and other personal identification of respondents were not stated throughout the study process to ensure anonymity and confidentiality.

Results {#S0003}
=======

From the beginning of 2014 to the end of 2018, a total of 502 children below 18 years of age were started ART. One hundred ninety-eight (198) cases were from Alamata General Hospital, 165 were from Mekelle General Hospital and the rest 139 were from Lemlem Karl hospital. Of those, 98 cases (41 from Alamata hospital, 33 from Mekelle hospital and 24 from Lemlem Karl) were excluded from analysis because of missing data on at least one of the 3 failure indicator variables (WHO stage, CD4 count and viral load) and due to short duration spent on ART (below 6 months). This is because first it is impossible to detect failure without one of the 3 criteria and secondly 6 months of effective ART follow-up is mandatory to diagnose treatment failure for a certain ART regimen. Finally, four hundred four (n=404) children aged between 6 months and 17 years who fulfilled the eligibility criteria were incorporated for analysis from three general hospitals of Mekelle and Southern zone of Tigray region.

Socio-Demographic Characteristics {#S0003-S2001}
---------------------------------

The study finding showed that from two hundred three (50.25%) female participants, 11.4% experience treatment failure. Of 106 (26%) children started ART below the age of five years, 6% failed to respond for first-line ART whereas 8% of those who started ART after 10 years old developed treatment failure. The result also notified that 149 (42%) study subjects were orphan children who lost either one or both parents; of those 41 (10.15%) were failed to respond to ART ([Table 1](#T0001){ref-type="table"}). Children followed for a minimum of 6 months and a maximum of 60 months with a median follow up of 24.3 months starting from January 2014 to the end of 2018.Table 1Distribution of Socio-Demographic Characteristics Among HIV/AIDS Infected Children in Public General Hospitals of Mekelle and Southern Zones of Tigray Region, Northern Ethiopia, 2019 (n=404)Independent VariablesCategoriesOutcome VariableFailedCensoredTotalFrequencyPercentFrequencyPercentAge at ART initiation\<5 yrs245.94%8220.3%106 (26.24)5--10409.9%9824.26%138 (34.16)\>10327.92%12831.68%160 (39.6)SexFemale4611.39%15738.86%203 (50.25)Male5012.38%15137.37%201 (49.75)Parent StatusBoth alive5513.6%20049.5%255 (63.12)Either Died215.2%7418.32%95 (23.51)Both Died204.95%348.41%54 (13.36)

Clinical Characteristics {#S0003-S2002}
------------------------

Among those who started ART with advanced WHO stage, 44.3% developed treatment failure. Meanwhile, 16.4% of children experienced treatment failure after initiating ART with either WHO stage one or two. The finding also revealed that 185 (46%) children did not have CD4 count after ART initiation and only 221 (55%) of them had access to a viral load of which only 64 (15.8%) had at baseline ([Table 2](#T0002){ref-type="table"}). Considerably, children acquired opportunistic infections at baseline as well as after initiation of ART were 39% and 24% respectively. Forty (47%) of children who had failed first-line treatment developed OI after started ART and 17% of the censored group acquired OI after treatment initiation ([Table 3](#T0003){ref-type="table"}).Table 2Clinical Characteristics of HIV/AIDS Infected Children in Public General Hospitals of Mekelle and Southern Zones of Tigray Region, Northern Ethiopia, 2019 (N=404)Independent VariablesCategoryOutcome VariableFailedCensoredTotal (%)FrequencyPercentFrequencyPercentWFA\< 3rd6716.58%17543.32%242 (59.90)3^rd^--97th297.18%12831.68%157 (38.86)\> 97th00%51.23%5 (1.23)HFA at baseline\< 3rd percentile8220.3%25663.36%338 (83.66)3rd--97th percentiles92.23%327.92%41(10.15)\> 97th percentile51.23%204.95%25 (6.19)WHO stage at ART startEarly-stage4912.13%24961.63%298 (73.76)Advanced stage4711.63%5914.6%106 (26.24)WHO stage at last visitEarly-stage6616.33%30876.24%374 (92.57)Advanced stage307.42%00%30 (7.42)CD4 count at baseline\<50102.47%40.99%14 (3.46)50--200102.47%297.18%39 (9.5)201--499276.68%8320.54%110 (27.23)≥500348.42%11027.23%144 (35.64)Unknown153.71%8220.3%97 (24.0)The most recent CD4 count\<5071.73%00%7 (1.73)50--200204.95%00%20 (4.95)201--499153.71%358.66%50 (12.38)≥500235.69%11929.45%142 (35.15)Unknown317.67%15438.12%185 (45.79)Access to viral loadNo245.94%15738.86%181 (44.8)Yes7217.82%15137.37%223 (55.2)VL at initiation\<100020.49%317.67%33 (8.17)1000--50,000163.96%112.72%27 (6.68)≥50,00040.99%00%4 (0.99)Unknown7418.32%26665.84%340 (84.16)Recent VL\<1000133.22%14936.88%162 (40.1)1000--50,000235.69%00%23 (5.69)≥50,000368.91%00%36 (8.91)Unknown245.94%15939.35%183 (45.3)[^1] Table 3Distribution of Opportunistic Infections Among HIV/AIDS Infected Children in Public General Hospitals of Mekelle and Southern Zones of Tigray Region, Northern Ethiopia, 2019 (n=404)Independent VariablesCategoryOutcome VariableTotal (%)FailedCensoredOpportunistic infections at baselineNo4611.39%20149.75%247 (61.14)YesAnemia40.99%112.72%15 (3.71)Diarrhea266.44%348.42%60 (14.85)SAM112.72%204.95%31 (7.67)TB194.7%317.67%50 (12.38)Pneumonia256.19%4511.14%70 (17.33)URTI81.98%174.21%25 (6.19)UTI20.49%20.49%4 (0.99)Candidiasis20.49%10.25%3 (0.74)Oral thrush20.49%40.99%6 (1.48)Meningitis10.25%40.99%5 (1.23)Total5012.38%10726.48%157 (38.86)Opportunistic infections after ART initiationNo5112.62%25563.12%306 (75.74)YesAnemia153.71%81.98%23 (5.69)Diarrhea133.22%133.22%26 (6.43)SAM153.71%71.73%22 (5.44)TB204.95%102.47%30 (7.42)Pneumonia235.69%153.71%38 (9.41)URTI51.23%143.46%19 (4.7)UTI00%40.99%4 (0.99)Candidiasis81.98%10.25%9 (2.23)Oral thrush20.49%40.99%6 (1.48)Meningitis30.74%30.74%6 (1.48)Total4511.14%5313.12%98 (24.23)[^2]

Treatment-Related and Other Factors {#S0003-S2003}
-----------------------------------

Three hundred twenty-nine (81.4%) participants started with NNRTIs based ART regimen with NVP-based dominating with 191 (47.3%) whereas 33 (8.2%) started with boosted PI (LPV/r) based regimen. Sixty (15%) children exposed previously to ART for PMTCT or PEP and 375 (93%) had taken cotrimoxazole and or INH as prophylaxis. One hundred fourteen children, (28%) started ART without knowing their serostatus; 110 (27%) had suboptimal adherence as well as 126 (31.2%) and 94 (23.3%) developed side effects and substituted their initial first-line regimen during follow up respectively. Moreover, 8 (2%) children died during follow up, 61 (15.1%) transferred out to other facilities, 37 (9.2%) lost as defaulters, and 31 (7.7%) switched to second-line ART regimen because of first-line regimen failure and other reasons.

Among the total 404 children in the study, 308 (76.24%) children were censored and 96 (23.8%; 95% CI 19.6, 27.9) experienced first-line treatment failure during the follow-up period. Of those 56 (58.3%), 19 (19.8%), and 18 (18.8%) were virological, immunological, and clinical failure respectively whereas the rest 3 (3.1%) found as combined failure fulfilling the diagnostic criteria for all the three types of failures. Alarmingly, 29 (30.2%) failures were reported within the first 12 months of the follow-up period. It is also awful that, from 96 children who failed for first-line, only 23 (24%) children were switched to second-line drugs after first-line treatment failure.

Comparison of Survival Status Using Kaplan Meier {#S0003-S2004}
------------------------------------------------

The Kaplan Meier failure curve increases stepwise and it crosses the failure function at failure probability of 0.5 ([Figure 1](#F0001){ref-type="fig"}).Figure 1Overall Kaplan Meier failure estimate of HIV/AIDS infected children in public general hospitals of Mekelle and Southern zones of Tigray Region, Northern Ethiopia, 2019 (n=404). The Y-axis represents the probability of failure whereas the X-axis indicates the analysis time in months.

Survival Function and an Incidence Density Rate of ART Failure {#S0003-S2005}
--------------------------------------------------------------

The total person-time observation was 11,061.5 person-months. The incidence rate of first-line ART regimen treatment failure was 8.7 (95% CI 7.10 to 10.60) per 1000 person-months of observation. The incidence of virological, immunological clinical and combined failure were 5.1 (95% CI 3.9 to 6.6), 1.7 (95% CI 1.1 to 2.7), 1.63 (95% CI 1.03 to 2.6) and 0.3 (95% CI 0.1 to 0.8) per 1000 person-months respectively. The median survival time was found to be 57.7 months (95% CI 54.8, 59.8). The cumulative probabilities of failure at the end of 12, 24, 36, 48 and 60 months were 0.08, 0.12, 0.20, 0.35 and 0.61 respectively.

Predictors of First-Line Treatment Failure {#S0003-S2006}
------------------------------------------

In the final Cox proportional hazard model, duration of follow up, advanced WHO stage, ART adherence and TB at baseline were found to be independent predictors of first-line ART treatment failure in HIV/AIDS infected children at 95% confidence level ([Table 4](#T0004){ref-type="table"}).Table 4Bi--Variable and Multi--Variable Analysis Output for HIV/AIDS Infected Children in Public General Hospitals of Mekelle and Southern Zones of Tigray Region, Northern Ethiopia, 2019 (n=404)Independent VariablesCategoryLast OutcomeP\>\|z\|Crude HR (95% CI)P\>\|z\|Adjusted HR (95% CI)FailedCensoredParent statusBoth alive55200----\--Either died21740.7731.08 (0.65--1.78)0.3840.75 (0.39--1.43)Both died20340.0081.99 (1.19--3.33)0.2391.48 (0.77--2.86)OI after initiationYes51255\<0.0012.63 (1.76--3.95)0.6721.17 (0.56--2.45)No4553\-\-\--Adherence to ARTOptimal47247\-\-\--Sub-optimal4961\<0.0013.3 (2.20--4.94)0.000\*2.84 (1.71--4.72)\*Disclosure statusNo32820.026\-\--Yes64226-0.61 (0.40--0.94)0.4000.78 (0.43--1.40)Follow up duration96308\<0.0010.88 (0.87--0.9)0.000\*0.85 (0.82--0.87)\*Baseline ART regimenNVP-based481430.0170.43 (0.21--0.86)0.0760.46 (0.19--1.09)ABC-based12300.4710.73 (0.32--1.70)0.9260.95 (0.35--2.58)EFV-based261120.0260.44 (0.21--0.91)0.2280.57 (0.22--1.43)LPV/r-based1023\-\-\--Baseline WHO stageEarly-stage49249\-\-\--Advanced stage4759\<0.0012.76 (1.85--4.14)0.4171.27 (0.71--2.27)Recent WHO stageEarly-stage66303\-\-\--Advanced stage305\<0.00110.1 (6.48--15.73)0.000\*5.21 (2.75--9.88)\*Anemia after startNo81300\-\-\--Yes158\<0.0014.68 (2.67--8.22)0.5920.81 (0.37--1.77)Drug substitutionNo70274\-\-\--Yes26340.051.34 (0.88--2.04)0.8601.04 (0.61--1.79)Diarrhea after startNo83295\-\-\--Yes13130.0032.83 (1.56--5.11)0.3121.56 (0.66--3.68)Pneumonia at baselineNo85288\-\-\--Yes11200.0051.93 (1.22--3.05)0.0770.54 (0.27--1.07)Malnutrition after startNo81301\-\-\--Yes1570.0014.90 (2.80--8.59)0.5860.77 (0.31--1.95)TB at baselineNo77277\-\-\--Yes1931\<0.0013.32 (1.99--5.55)0.022\*2.27 (1.12--4.56)\*TB after initiationNo76298\-\-\--Yes20100.0012.55 (1.55--4.20)0.5221.32 (0.56--3.13)Pneumonia after startNo73293\-\-\--Yes2315\<0.0012.83 (1.77--4.54)0.2561.5 (0.75--3.01)[^3][^4]

Children who started ART with sub-optimal adherence were observed to have a 3 times higher hazard of first-line treatment failure \[AHR=2.84; 95% CI 1.71--4.72\] than their counterparts. In addition to this, children who diagnosed as advanced WHO stage at last visit had 5.2 times higher hazard than those who defined as in the early WHO stages \[AHR=5.21; 95% CI 2.75--9.88\].

The other factor that showed significant association was the duration of ART follow-up. Children who had been on ART for a long period were less likely to develop treatment failure. For each month increase in the duration of ART follow up, the hazard of developing treatment failure will decrease by 15% \[AHR=0.85; 95% CI 0.82--0.87\]. Moreover, those children who had tuberculosis infection at baseline were also 2.3 times at higher hazard of experiencing treatment failure than those with no TB infection at ART initiation \[AHR=2.27, 95% CI 1.12--4.57\].

Discussion {#S0004}
==========

This study was conducted to determine the incidence and predictors of first-line ART failure among HIV/AIDS infected children receiving first-line ART. The incidence rate of first-line ART regimen treatment failure was 8.7 (95% CI 7.10 to 10.60) per 1000 person-months of observation. The median survival time was found to be 57.7 months (95% CI 54.8, 59.8) with 0.61 cumulative probability of failure at the end of 60 months. Having a short duration of follow-up, advanced WHO stage at follow up visit, ART non-adherence, and TB at baseline was found to be independent predictors of first-line ART treatment failure.

In this study, the median survival time was 57.7 months (95% CI 54.83, 59.77) which is longer than the findings of studies in India; 43 months,[@CIT0026] a combined study in Mozambique and Uganda; 12.6 months[@CIT0027] and Uganda; 26.4 months.[@CIT0028] This could be explained by the improvements in the therapeutic and diagnostic measures in current visits from then and the increase in access and variety of more potent drugs nowadays than the past periods.[@CIT0007] The other reason may be the Ugandan study considered treatment failures which occur before six months of follow up which is not the case in this study.

The incidence rate of first-line ART failure was 8.7 (95% CI 7.10 to 10.60) per 1000 person-months which is found to be higher than the finding in the Amhara region, 2.2 (95% CI 1.72 to 2.82) per 1000 person-months observations.[@CIT0025] This may be due to the difference in person-time observations. The total person-time observation was 28, 562.5 person-months which is much more than the current study, 11, 061 person-months. The other possible reason might be that they determine failure rate only by immunologic and clinical criteria which could further lengthen the time to detection than viral load criteria.[@CIT0006]

Children who started ART regimens while having tuberculosis had 2.3 times more hazard of failure than those with no TB at ART initiation \[AHR=2.27; 95% CI 1.12--4.56\]. This finding was supported by the report of a combined study conducted in Mozambique and Uganda (24). This might be because TB increases HIV replication through the process of immune activation leading to increased viral load. This results in a more rapid progression of HIV disease which counteracts with the action of ART drugs.[@CIT0007]

This study revealed that the WHO clinical stage at last visit was significantly associated with first-line ART failure (AHR=5.21; 95% CI 2.75--9.88). No other earlier studies examined the WHO stage at the last follow up visit. However, baseline WHO stage was stated as a predictor of treatment failure in findings of Mozambique and Uganda study[@CIT0027] and the study at Fiche and Kuyu hospitals[@CIT0029] which is not significant in the current study. This difference could be rationalized because the current guideline-recommended is more advanced management and short follow up visits;[@CIT0007] so that those children who had advanced WHO stage at ART initiation might receive strict and close intervention in terms of treatment regimen selection, laboratory investigations, and repeated follow up visits.

The current study also showed that children those having sub-optimal adherence for ART regimens were 3 times at higher hazard of experiencing first-line ART failure compared to their counterparts (AHR=2.84 95% CI 1.71--4.72). This finding was conformable with the results of previous studies at Fiche and Kuyu hospitals, Oromia,[@CIT0029] Rwanda,[@CIT0030] Uganda[@CIT0028] and Tanzania.[@CIT0031] This is because a high level of sustained adherence is necessary to suppress viral replication and improve immunological and clinical outcomes which in turn decrease the risk of developing ARV drug resistance and reduce the risk of transmitting HIV. To the contrary, poor adherence to ART drugs is commonly encountered in the treatment of children and adolescents living with HIV due to a variety of factors including regimens for children often require taking multiple pills with frequent dosing requirements each with potential adverse effects and drug interaction, limited choice of pediatric formulations and poor palatability of liquid formulations. A child's age and developmental stage may also influence adherence since this age group needs support from others to take medication timely and also may face difficulties in swallowing tablets.[@CIT0006],[@CIT0007]

A long duration of follow up was also reported as having a protective effect on first-line ART failure (AHR=0.85; 95% CI 0.82--0.87). This finding is similar to the finding of a study done in Amhara region hospitals.[@CIT0025] Amazingly, 29 (30.2%) of failures had occurred in the first twelve months of follow up after ART initiation. Several reasons could be stated for this. For example; different rapid effects like IRIS were very common in the early months after ART start, adherence level of children might increase with time and might be considerably lower in the first few months, and the need for adaptation to daily ART drug intake may hinder the patient's response to ART regimen and increase the chance of failure.[@CIT0006]

Conclusion {#S0005}
==========

The incidence rate of ART failure remains unacceptably high in this study since it is higher than the maximum expected level of the virological failure rate of 20% and far less than 10% of failure rate sated by UNAIDS projection for 2020. Even though efforts are taken to increase ART access, the issue of inadequate viral suppression and increased treatment failure rate becomes a burning issue these days. Moreover, children who had TB at ART initiation, advanced WHO clinical stage after ART initiation, non-adherence to ART regimen, and those who were on ART for a short period were at higher hazard of treatment failure.
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[^1]: **Abbreviation:** WFA, weight for age; HFA, height for age; WHO, world health organization; VL, viral load.

[^2]: **Abbreviation:** TB, tuberculosis; SAM, severe acute malnutrition; URTI, upper respiratory tract infection; UTI, urinary tract infection.

[^3]: **Note:** \*significant at 5% level of significance.

[^4]: **Abbreviations:** NVP, nevirapine; ABC, abacavir; EFZ, Efavirenz; LPV/r, lopinavir/ritonavir; VL, viral load; OI, opportunistic infection; ART, anti retroviral therapy; WHO, world health organization; TB, tuberculosis.
